Table 2.

Diagnostic performance of MRI on axillary lymph node metastasis per molecular subtype and subgroup analysis

N = 2473	Total	Luminal A	Luminal B1	Luminal B2	HER-2	TNBC
Sensitivity %(95% CI)	63.2 (60–67)	53.8 (47–60)	65.5 (61–72)	67.9 (60–77)	62.5 (49–75)	77.8 (64–88)
Specificity % (95% CI)	68.5 (67–71)	76.2 (73–80)	67.1 (63–73)	63.0 (55–70)	57.1 (48–66)	57.6 (49–66)
PPV % (95% CI)	51.7 (48–54)	48.5 (42–54)	58.2 (54–65)	58.7 (50–66)	40.7 (30–52)	42.9 (33–53)
NPV % (95% CI)	77.7 (77–81)	79.7 (77–83)	73.5 (70–78)	71.7 (65–80)	76.4 (66–85)	86.4 (77–93)
Accuracy % (95% CI)	66.6 (65–69)	69.5 (67–73)	66.4 (64–71)	65.1 (60–71)	58.9 (51–66)	63.4 (56–70)

	N0	N1	N2	N3	N0 + N1	N2 + N3
Sensitivity % (95% CI)		57.1 (54–62)	78.2 (70–85)	86.7 (76–93)	57.1 (54–62)	81.1 (75–86)
Specificity % (95% CI)	68.5 (67–71)				68.5 (67–71)
PPV % (95% CI)		100 (99–100)	100 (97–100)	100 (94–100)	42.1 (38–45)	100 (98–100)
NPV % (95% CI)	100 (100–100)				80.0 (79–83)

TNBC triple-negative breast cancer, HER-2 human epidermal growth factor receptor 2, CI confidence interval, NPV negative predictive value, PPV positive predictive value